The most common side effect of sodium–glucose co-transporter 2 (SGLT2) inhibitors is genital tract infections. However, a few case reports have shown that their use may induce postoperative euglycemic diabetic ketoacidosis (DKA). Herein, we report two cases of patients who received SGLT2 inhibitor dapagliflozin preoperatively; DKA developed a few days after the operation. To the best of our knowledge, these cases are the first and second reported cases of dapagliflozin-induced DKA after orthopedic surgery. We suggest changing the use of SGLT2 inhibitors to the use of insulin preoperatively and adequate fluid replacement to prevent this life-threatening complication.